The purpose of the study is to characterize the absorption, distribution, metabolism and excretion (ADME) of a single oral dose of \[14C\] CC-99677.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
8
Specified dose on specified days
Local Institution - 0001
Madison, Wisconsin, United States
Maximum plasma concentration of the drug (Cmax) for CC-99677
Time frame: Up to 15 days
Time of maximum observed plasma concentration (Tmax) for CC-99677
Time frame: Up to 15 days
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) for CC-99677
Time frame: Up to 15 days
Total radioactivity recovered in urine (UR)
Time frame: Up to 15 days
Percent of total radioactivity recovered in urine (%UR)
Time frame: Up to 15 days
Total radioactivity recovered in feces (FR)
Time frame: Up to 15 days
Percent of total radioactivity recovered in feces (%FR)
Time frame: Up to 15 days
Total radioactivity recovered in bile (BR)
Time frame: Up to 15 days
Total radioactivity recovered in urine, feces, and bile combined (Rtotal)
Time frame: Up to 15 days
Percent of total radioactivity recovered in all excreta (%Total)
Time frame: Up to 15 days
Plasma AUC (total radioactivity (TRA))/Blood AUC (TRA)
Time frame: Up to 15 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Incidence of adverse events (AEs)
Time frame: Up to 50 days
Incidence of serious adverse events (SAEs)
Time frame: Up to 50 days
Incidence of AEs leading to discontinuation
Time frame: Up to 15 days
Incidence of vital sign abnormalities
Time frame: Up to 15 days
Incidence of electrocardiogram (ECG) abnormalities
Time frame: Up to 15 days
Incidence of physical examination abnormalities
Time frame: Up to 15 days
Incidence of clinical laboratory test abnormalities
Time frame: Up to 15 days
Cmax
Time frame: Up to 15 days
Tmax
Time frame: Up to 15 days
AUC(0-T)
Time frame: Up to 15 days